Erratum: Phase i clinical, pharmacokinetic, and pharmacodynamic study of KOS-862 (Epothilone D) in patients with advanced solid tumors and lymphoma (Investigational New Drugs DOI 10.1007/s10637-011-9765-7);Phase i clinical, pharmacokinetic, and pharmacodynamic study of KOS-862 (Epothilone D) in patients with advanced solid tumors and lymphoma

Investigational New Drugs

Volumn 30, Issue 6, 2012, Pages 2294-2302

  Konner, Jason ^a   Grisham, Rachel N ^a   Park, Jae ^a   O'Connor, Owen A ^b   Cropp, Gillian ^c   Johnson, Robert ^d   Hannah, Alison L ^c   Hensley, Martee L ^a   Sabbatini, Paul ^a   Miranov, Svetlana ^a   Danishefsky, Samuel ^a   Hyman, David ^a   Spriggs, David R ^a   Dupont, Jakob ^e   Aghajanian, Carol ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b NEW YORK UNIVERSITY   (United States)

^c Nereus Pharmaceuticals Inc   (United States)

^d Aeolian Biomed   (United States)

^e GENENTECH INC   (United States)

Author keywords

Epothilone; Epothilone D; KOS 862; Lymphoma; Solid tumors

Indexed keywords

EPOTHILONE D; TUMOR MARKER;

ADULT; ADVANCED CANCER; AGED; ANEMIA; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; COLORECTAL CANCER; CONFUSION; CONTROLLED STUDY; DEHYDRATION; DIARRHEA; DIZZINESS; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG TOLERABILITY; FAINTNESS; FEMALE; HUMAN; HYPESTHESIA; LUNG NON SMALL CELL CANCER; LYMPHOMA; MALE; MICROTUBULE; MULTIPLE CYCLE TREATMENT; NAUSEA; OVARY CANCER; PARESTHESIA; PERIPHERAL NEUROPATHY; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; SENSORY NEUROPATHY; SOLID TUMOR; VISUAL HALLUCINATION; VOMITING; WEAKNESS;

EID: 84875534174     PISSN: 01676997     EISSN: 15730646     Source Type: Journal    
DOI: 10.1007/s10637-011-9780-8     Document Type: Erratum

References (45)

1. Schiff PB, Fant J, Horwitz SB (1979) Promotion of microtubule assembly in vitro by taxol. Nature 277(5698):665-667
2. Yvon AM, Wadsworth P, Jordan MA (1999) Taxol suppresses dynamics of individual microtubules in living human tumor cells. Mol Biol Cell 10(4):947-959
3. Altmann KH, Wartmann M, O'Reilly T (2000) Epothilones and related structures-a new class of microtubule inhibitors with potent in vivo antitumor activity. Biochim Biophys Acta 1470(3):M79-M91
4. Horwitz SB et al (1993) Taxol: mechanisms of action and resistance. J Natl Cancer Inst Monogr 15:55-61
5. Jachez B, Nordmann R, Loor F (1993) Restoration of taxol sensitivity of multidrug-resistant cells by the cyclosporine SDZ PSC 833 and the cyclopeptolide SDZ 280-446. J Natl Cancer Inst 85(6):478-483
6. Nogales E et al (1995) Structure of tubulin at 6.5 A and location of the taxol-binding site. Nature 375(6530):424-427
7. Rowinsky EK et al (1993) Clinical toxicities encountered with paclitaxel (Taxol). Semin Oncol 20(4 Suppl 3):1-15
8. Rose WC (1992) Taxol: a review of its preclinical in vivo antitumor activity. Anticancer Drugs 3(4):311-321
9. Kowalski RJ, Giannakakou P, Hamel E (1997) Activities of the microtubule-stabilizing agents epothilones A and B with purified tubulin and in cells resistant to paclitaxel (Taxol(R)). J Biol Chem 272(4):2534-2541
10. Nettles JH et al (2004) The binding mode of epothilone A on alpha, beta-tubulin by electron crystallography. Science 305(5685):866-869
11. Gerth K et al (1996) Epothilons A and B: antifungal and cytotoxic compounds from Sorangium cellulosum (Myxobacteria). Production, physico-chemical and biological properties. J Antibiot (Tokyo) 49(6):560-563
12. Lee SH et al (2007) Epothilones induce human colon cancer SW620 cell apoptosis via the tubulin polymerization independent activation of the nuclear factor-kappaB/IkappaB kinase signal pathway. Mol Cancer Ther 6(10):2786-2797
13. Cheng KL, Bradley T, Budman DR (2008) Novel microtubule-targeting agents-the epothilones. Biologics 2(4):789-811
14. Trivedi M et al (2008) Epothilones: a novel class of microtubule- stabilizing drugs for the treatment of cancer. Future Oncol 4(4):483-500
15. Harrison M, Swanton C (2008) Epothilones and new analogues of the microtubule modulators in taxane-resistant disease. Expert Opin Investig Drugs 17(4):523-546
16. Goodin S, Kane MP, Rubin EH (2004) Epothilones: mechanism of action and biologic activity. J Clin Oncol 22(10):2015-2025
17. Nicolaou KC et al (1997) Synthesis of epothilones A and B in solid and solution phase. Nature 387(6630):268-272
18. Chou TC et al (1998) Desoxyepothilone B is curative against human tumor xenografts that are refractory to paclitaxel. Proc Natl Acad Sci USA 95(26):15798-15802
19. Skehan P et al (1990) New colorimetric cytotoxicity assay for anticancer-drug screening. J Natl Cancer Inst 82(13):1107-1112
20. Chou TC et al (2001) The synthesis, discovery, and development of a highly promising class of microtubule stabilization agents: curative effects of desoxyepothilones B and F against human tumor xenografts in nude mice. Proc Natl Acad Sci USA 98(14):8113-8118
21. Chou TC et al (1998) Desoxyepothilone B: an efficacious microtubule-targeted antitumor agent with a promising in vivo profile relative to epothilone B. Proc Natl Acad Sci USA 95 (16):9642-9647
22. Holen K (2004) Phase I study using continuous intravenous (CI) KOS-862 (Epothilone D) in patients with solid tumors. Proc Am Soc Clin Oncol, abstract 2024
23. Piro L (2003) KOS-862 (epothilone D): a comparison of two schedules in patients with advanced malignancies. Proc Am Soc Clin Oncol 22(abstract 539)
24. Arnold D et al (2009) Weekly administration of sagopilone (ZK-EPO), a fully synthetic epothilone, in patients with refractory solid tumours: results of a phase I trial. Br J Cancer 101(8):1241-1247
25. Lam ET et al (2011) Phase I dose escalation study of KOS-1584, a novel epothilone, in patients with advanced solid tumors. Cancer Chemother Pharmacol
26. Perez EA et al (2007) Efficacy and safety of ixabepilone (BMS-247550) in a phase II study of patients with advanced breast cancer resistant to an anthracycline, a taxane, and capecitabine. J Clin Oncol 25(23):3407-3414
27. Roche H et al (2007) Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, as first-line therapy in patients with metastatic breast cancer previously treated with anthracycline chemotherapy. J Clin Oncol 25(23):3415-3420
28. Chen T, Molina A, Moore S et al (2004) Epothilone B analog (BMS-247550) at the recommended phase II dose (RPTD) in patients (pts) with gynecologic (gyn) and breast cancers. Proc Am Soc Clin Oncol 22(2115a).
29. Smit W, Sufliarsky J, Spanik S et al (2005) Phase I/II dose-escalation trial of patupilone every 3 weeks in patients with relapsed/refractory ovarain cancer. Proc Am Soc Clin Oncol 23(5056a).
30. Vansteenkiste J et al (2007) Phase II clinical trial of the epothilone B analog, ixabepilone, in patients with non small-cell lung cancer whose tumors have failed first-line platinum-based chemotherapy. J Clin Oncol 25(23):3448-3455
31. Burtness B, Goldwasser M, Axelrod R et al (2006) A randomized phase II study of BMS-247550 (ixabepilone) given daily×5 days every 3 weeks or weekly in patients with metastatic or recurrent squamous cell cancer of the head and neck. Proc Am Soc Clin Oncol 24(5532a)
32. Altmann KH (2005) Recent developments in the chemical biology of epothilones. Curr Pharm Des 11(13):1595-1613
33. Beer TM et al (2007) Phase II study of KOS-862 in patients with metastatic androgen independent prostate cancer previously treated with docetaxel. Invest New Drugs 25(6):565-570
34. Feldman DR et al (2007) Phase II trial of ixabepilone in patients with cisplatin-refractory germ cell tumors. Invest New Drugs 25(5):487-490
35. Whitehead RP et al (2006) A Phase II trial of epothilone B analogue BMS-247550 (NSC #710428) ixabepilone, in patients with advanced pancreas cancer: a Southwest Oncology Group study. Invest New Drugs 24(6):515-520
36. Ajani JA et al (2006) A multi-center phase II study of BMS-247550 (Ixabepilone) by two schedules in patients with metastatic gastric adenocarcinoma previously treated with a taxane. Invest New Drugs 24(5):441-446
37. Eng C et al (2004) A phase II trial of the epothilone B analog, BMS-247550, in patients with previously treated advanced colorectal cancer. Ann Oncol 15(6):928-932
38. Posadas EM et al (2007) A phase II study of ixabepilone (BMS-247550) in metastatic renal-cell carcinoma. Cancer Biol Ther 6 (4):490-493
39. Smith S, Pro B, Van Besien K et al (2005) A phase II study of epothilone B analog BMS-247550 (NSC 710428) in patients with relapsed aggresive non-Hodgkin's lymphomas. Proc Am Soc Clin Oncol 23(6625a)
40. Galsky MD et al (2005) Multi-institutional randomized phase II trial of the epothilone B analog ixabepilone (BMS-247550) with or without estramustine phosphate in patients with progressive castrate metastatic prostate cancer. J Clin Oncol 23(7):1439-1446
41. Hensley ML et al (2007) A phase I trial of BMS-247550 (NSC# 710428) and gemcitabine in patients with advanced solid tumors. Invest New Drugs 25(4):335-341
42. Forster M et al (2007) A phase Ib and pharmacokinetic trial of patupilone combined with carboplatin in patients with advanced cancer. Clin Cancer Res 13(14):4178-4184
43. Plummer R (2002) Phase I and pharmakokinetic study of BMS-247-550 in combination with carboplatin in patients with advanced solid malignancies. Proc Am Soc Clin Oncol, abstract 2125
44. Faivre S (2004) Phase I study of ixabepilone given every other week in combination with irinotecan in patients with advanced malignancies. Proc Am Soc Clin Oncol, abstract 2051
45. Wojtowicz M (2004) Phase I dose-escalation trial investigating the safety and tolerability of EPO906 plus estramustine in patients with advanced cancer Proc Am Soc Clin Oncol, abstract 4623